Phathom Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company focuses on acid-related gastrointestinal disorders, making it a specialty pharma name rather than a broad diversified healthcare group. Phathom was launched in 2019 through a collaboration between Takeda Pharmaceutical and Frazier Healthcare Partners, with the aim of building a company dedicated to the development and commercialization of novel GI therapies. Its headquarters are in New Jersey, and its operating model is largely centered on the U.S. market, where it is building a commercial franchise around its lead asset. The company’s core product platform is VOQUEZNA, a vonoprazan-based franchise designed for the treatment of gastroesophageal reflux disease and related acid-mediated conditions. Phathom markets VOQUEZNA tablets, as well as VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which are used in H. pylori eradication regimens. From an investment perspective, this gives Phathom a differentiated position in a large and clinically meaningful GI market, with a product set that is protected by intellectual property and supported by a distinct mechanism of action. In a competitive landscape that includes large pharmaceutical companies and established generic therapies, Phathom’s edge comes from innovation, product labeling, and the commercial adoption of a novel acid-suppression platform. Commercial execution has become the key storyline. Recent company disclosures show that prescription growth accelerated through 2025, with more than 580,000 filled prescriptions for the VOQUEZNA franchise through late July 2025 and more than one million cumulative prescriptions in the United States by the fourth quarter of 2025. Those milestones indicate that Phathom has moved beyond launch phase and into a more visible commercialization stage. At the same time, the company remains a specialty pharma growth story with the usual risks: reliance on a limited product portfolio, the need to maintain physician awareness and payer access, and the pressure to fund sales and marketing while continuing to scale revenue. Phathom’s strategic relevance for investors lies in the combination of a focused GI franchise, a U.S.-only commercial emphasis, and a product that is still early in its adoption curve. The company is not a broad healthcare platform; it is a concentrated bet on whether VOQUEZNA can become a durable commercial standard in acid-related GI disease in the United States. For French-speaking investors in France, Belgium, and Switzerland, the case is best viewed as a U.S. NASDAQ specialty pharma story with meaningful upside tied to execution, uptake, and reimbursement dynamics rather than to a diversified portfolio of assets.